GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rocket Pharmaceuticals Inc (STU:9IP1) » Definitions » Cyclically Adjusted PB Ratio

Rocket Pharmaceuticals (STU:9IP1) Cyclically Adjusted PB Ratio : 0.27 (As of Jul. 18, 2025)


View and export this data going back to 2015. Start your Free Trial

What is Rocket Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2025-07-18), Rocket Pharmaceuticals's current share price is €2.46. Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €9.01. Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.27.

The historical rank and industry rank for Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:9IP1' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 0.36
Current: 0.36

During the past years, Rocket Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.36. The lowest was 0.00. And the median was 0.00.

STU:9IP1's Cyclically Adjusted PB Ratio is ranked better than
77.58% of 678 companies
in the Biotechnology industry
Industry Median: 1.66 vs STU:9IP1: 0.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Rocket Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2025 was €3.571. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €9.01 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Rocket Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 3.75 1.44

Rocket Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.35 2.69 2.28 1.44 0.77

Competitive Comparison of Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


;
;

Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.46/9.01
=0.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rocket Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Rocket Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=3.571/134.9266*134.9266
=3.571

Current CPI (Mar. 2025) = 134.9266.

Rocket Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201506 6.924 100.684 9.279
201509 15.717 100.392 21.124
201512 15.121 99.792 20.445
201603 13.491 100.470 18.118
201606 12.616 101.688 16.740
201609 11.255 101.861 14.909
201612 10.281 101.863 13.618
201703 8.767 102.862 11.500
201706 7.582 103.349 9.899
201709 6.296 104.136 8.158
201712 5.930 104.011 7.693
201803 3.502 105.290 4.488
201806 3.403 106.317 4.319
201809 3.090 106.507 3.915
201812 3.774 105.998 4.804
201903 3.474 107.251 4.370
201906 4.370 108.070 5.456
201909 4.182 108.329 5.209
201912 5.050 108.420 6.285
202003 4.696 108.902 5.818
202006 4.290 108.767 5.322
202009 3.720 109.815 4.571
202012 6.786 109.897 8.332
202103 6.504 111.754 7.853
202106 6.403 114.631 7.537
202109 6.406 115.734 7.468
202112 6.239 117.630 7.156
202203 5.877 121.301 6.537
202206 5.571 125.017 6.013
202209 5.469 125.227 5.893
202212 5.842 125.222 6.295
202303 5.330 127.348 5.647
202306 4.619 128.729 4.841
202309 5.624 129.860 5.843
202312 5.003 129.419 5.216
202403 4.481 131.776 4.588
202406 3.929 132.554 3.999
202409 3.261 133.029 3.308
202412 4.156 133.157 4.211
202503 3.571 134.927 3.571

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Rocket Pharmaceuticals  (STU:9IP1) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Rocket Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Rocket Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Rocket Pharmaceuticals Business Description

Traded in Other Exchanges
Address
9 Cedarbrook Drive, Cranbury, NJ, USA, 08512
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.

Rocket Pharmaceuticals Headlines

No Headlines